RESUMO
Lysophosphatidylcholine (LPC) is present in various foods and contains a choline moiety such as in glycerophosphocholine (GPC). However, the potential of LPC as a choline source remains unclear. This study investigated the single-dose pharmacokinetics of 480 mg soy-derived LPC in 12 healthy men compared with that of either soy oil with the same lipid amount (placebo) or GPC with the same choline amount. Both LPC and GPC supplementation increased plasma choline, serum phospholipid, and serum triglyceride concentrations, but neither of them significantly elevated plasma trimethylamine N-oxide concentration. In addition, although the intake of LPC slightly increased plasma LPC16:0, LPC18:2, and total LPC concentrations, their concentrations remained within physiological ranges. No adverse events were attributed to the LPC supplementation. To the best of our knowledge, this study is the first to compare LPC and GPC pharmacokinetics in humans and shows that LPC can be a source of choline.
Assuntos
Colina , Glicerilfosforilcolina , Glycine max , Lisofosfatidilcolinas , Humanos , Masculino , Lisofosfatidilcolinas/sangue , Glicerilfosforilcolina/farmacocinética , Glicerilfosforilcolina/sangue , Colina/farmacocinética , Colina/sangue , Adulto , Glycine max/química , Suplementos Nutricionais , Adulto Jovem , Triglicerídeos/sangue , Metilaminas/sangue , Metilaminas/farmacocinéticaRESUMO
Linerixibat, an oral small-molecule ileal bile acid transporter inhibitor under development for cholestatic pruritus in primary biliary cholangitis, was designed for minimal absorption from the intestine (site of pharmacological action). This study characterized the pharmacokinetics, absorption, metabolism, and excretion of [14C]-linerixibat in humans after an intravenous microtracer concomitant with unlabeled oral tablets and [14C]-linerixibat oral solution. Linerixibat exhibited absorption-limited flip-flop kinetics: longer oral versus intravenous half-life (6-7 hours vs. 0.8 hours). The short intravenous half-life was consistent with high systemic clearance (61.9 l/h) and low volume of distribution (16.3 l). In vitro studies predicted rapid hepatic clearance via cytochrome P450 3A4 metabolism, which predicted human hepatic clearance within 1.5-fold. However, linerixibat was minimally metabolized in humans after intravenous administration: â¼80% elimination via biliary/fecal excretion (>90%-97% as unchanged parent) and â¼20% renal elimination by glomerular filtration (>97% as unchanged parent). Absolute oral bioavailability of linerixibat was exceedingly low (0.05%), primarily because of a very low fraction absorbed (0.167%; fraction escaping first-pass gut metabolism (fg) â¼100%), with high hepatic extraction ratio (77.0%) acting as a secondary barrier to systemic exposure. Oral linerixibat was almost entirely excreted (>99% recovered radioactivity) in feces as unchanged and unabsorbed linerixibat. Consistent with the low oral fraction absorbed and â¼20% renal recovery of intravenous [14C]-linerixibat, urinary elimination of orally administered radioactivity was negligible (<0.04% of dose). Linerixibat unequivocally exhibited minimal gastrointestinal absorption and oral systemic exposure. Linerixibat represents a unique example of high CYP3A4 clearance in vitro but nearly complete excretion as unchanged parent drug via the biliary/fecal route. SIGNIFICANCE STATEMENT: This study conclusively established minimal absorption and systemic exposure to orally administered linerixibat in humans. The small amount of linerixibat absorbed was eliminated efficiently as unchanged parent drug via the biliary/fecal route. The hepatic clearance mechanism was mispredicted to be mediated via cytochrome P450 3A4 metabolism in vitro rather than biliary excretion of unchanged linerixibat in vivo.
Assuntos
Administração Intravenosa , Administração Oral , Proteínas de Transporte/antagonistas & inibidores , Eliminação Hepatobiliar , Glicoproteínas de Membrana/antagonistas & inibidores , Metilaminas/farmacocinética , Eliminação Renal , Tiazepinas/farmacocinética , Adulto , Disponibilidade Biológica , Fármacos Gastrointestinais/farmacocinética , Voluntários Saudáveis , Eliminação Hepatobiliar/efeitos dos fármacos , Eliminação Hepatobiliar/fisiologia , Humanos , Absorção Intestinal , Masculino , Taxa de Depuração Metabólica , Eliminação Renal/efeitos dos fármacos , Eliminação Renal/fisiologia , Resultado do TratamentoRESUMO
Synthetic cathinones, such as methylone and pentedrone, are psychoactive derivatives of cathinone, sold in the internet as "plant food" or "bath salts". However, the level at which these compounds and their enantiomers cross the intestinal barrier has not been yet determined. Thus, the present study aimed to analyze the enantioselectivity on the permeability of these drugs through the intestinal barrier by using the Caco-2 cell line, a widely used in vitro model for drug permeability studies. To achieve this goal, an UHPLC-UV method was developed and validated to quantify both synthetic cathinones. The developed UHPLC-UV method revealed high selectivity and a linearity from 1 to 500 µM with correlation coefficients always higher than 0.999. The method has an accuracy that ranged between 89 and 107%, inter-day and intra-day precisions with coefficients of variation below 10%, limits of detection and quantification of 0.31 µM and 0.93 µM for methylone and 0.17 µM and 0.52 µM for pentedrone, respectively. In Caco-2 cells, a differentiated passage of the enantiomers across monolayer was observed for both cathinones. For pentedrone, the difference was observed after the first hour, being R-(-)-pentedrone the most permeable compound. Regarding methylone, the difference was noted after one hour and 30 min, with S-(-)-methylone being the most absorbed enantiomer. In conclusion, a fully validated method was successfully applied for studying the permeability of methylone and pentedrone enantiomers in an in vitro model of human intestine, which allowed to discover, for the first time, the enantioselectivity in drug permeability of this class of drugs.
Assuntos
Cromatografia Líquida de Alta Pressão/métodos , Absorção Intestinal/fisiologia , Metanfetamina/análogos & derivados , Metilaminas/química , Metilaminas/farmacocinética , Pentanonas/química , Pentanonas/farmacocinética , Alcaloides/química , Células CACO-2 , Humanos , Metanfetamina/química , Metanfetamina/farmacocinética , Permeabilidade , Psicotrópicos , Sensibilidade e Especificidade , Estereoisomerismo , Relação Estrutura-AtividadeRESUMO
OBJECTIVE: The gut microbiota-derived metabolite, trimethylamine N-oxide (TMAO) plays an important role in cardiovascular disease (CVD). The fasting plasma TMAO was shown as a prognostic indicator of CVD incident in patients and raised the interest of intervention targeting gut microbiota. Here we develop a clinically applicable method called oral carnitine challenge test (OCCT) for TMAO-related therapeutic drug efforts assessment and personalising dietary guidance. DESIGN: A pharmacokinetic study was performed to verify the design of OCCT protocol. The OCCT was conducted in 23 vegetarians and 34 omnivores to validate gut microbiota TMAO production capacity. The OCCT survey was integrated with gut microbiome, host genotypes, dietary records and serum biochemistry. A humanised gnotobiotic mice study was performed for translational validation. RESULTS: The OCCT showed better efficacy than fasting plasma TMAO to identify TMAO producer phenotype. The omnivores exhibited a 10-fold higher OR to be high TMAO producer than vegetarians. The TMAO-associated taxa found by OCCT in this study were consistent with previous animal studies. The TMAO producer phenotypes were also reproduced in humanised gnotobiotic mice model. Besides, we found the faecal CntA gene was not associated with TMAO production; therefore, other key relevant microbial genes might be involved. Finally, we demonstrated the urine TMAO exhibited a strong positive correlation with plasma TMAO (r=0.92, p<0.0001) and improved the feasibility of OCCT. CONCLUSION: The OCCT can be used to identify TMAO-producer phenotype of gut microbiota and may serve as a personal guidance in CVD prevention and treatment. TRIAL REGISTRATION NUMBER: NCT02838732; Results.
Assuntos
Carnitina/farmacologia , Disbiose , Comportamento Alimentar/fisiologia , Microbioma Gastrointestinal/fisiologia , Metilaminas , Animais , Doenças Cardiovasculares/metabolismo , Doenças Cardiovasculares/prevenção & controle , Carnitina/metabolismo , Dieta/métodos , Disbiose/diagnóstico , Disbiose/metabolismo , Humanos , Metilaminas/metabolismo , Metilaminas/farmacocinética , Camundongos , Oxidantes/metabolismo , Oxidantes/farmacocinética , Prognóstico , Eliminação Renal/fisiologiaRESUMO
DS86760016 is a new leucyl-tRNA-synthetase inhibitor at the preclinical development stage. DS86760016 showed potent activity against extended-spectrum multidrug-resistant Pseudomonas aeruginosa isolated from clinical samples and in vitro biofilms. In a murine catheter-associated urinary tract infection model, DS86760016 treatment resulted in significant eradication of P. aeruginosa from the kidney, bladder, and catheter without developing drug resistance. Our data suggest that DS86760016 has the potential to act as a new drug for the treatment of Pseudomonas infections.
Assuntos
Antibacterianos/farmacologia , Compostos de Boro/farmacologia , Infecções Relacionadas a Cateter/tratamento farmacológico , Dioxóis/farmacologia , Leucina-tRNA Ligase/antagonistas & inibidores , Metilaminas/farmacologia , Infecções por Pseudomonas/tratamento farmacológico , Pseudomonas aeruginosa/efeitos dos fármacos , Infecções Urinárias/tratamento farmacológico , Animais , Antibacterianos/farmacocinética , Biofilmes/crescimento & desenvolvimento , Compostos de Boro/farmacocinética , Infecções Relacionadas a Cateter/microbiologia , Dioxóis/farmacocinética , Modelos Animais de Doenças , Farmacorresistência Bacteriana Múltipla , Feminino , Humanos , Metilaminas/farmacocinética , Camundongos , Testes de Sensibilidade Microbiana , Infecções por Pseudomonas/microbiologia , Infecções Urinárias/microbiologiaRESUMO
BACKGROUND: Pruritus (itch) is a symptom commonly experienced by patients with cholestatic liver diseases such as primary biliary cholangitis (PBC, previously referred to as primary biliary cirrhosis). Bile acids (BAs) have been proposed as potential pruritogens in PBC. The ileal bile acid transporter (IBAT) protein expressed in the distal ileum plays a key role in the enterohepatic circulation of BAs. Pharmacological inhibition of IBAT with GSK2330672 may reduce BA levels in the systemic circulation and improve pruritus. METHODS: This clinical study (BAT117213 study) is sponsored by GlaxoSmithKline (GSK) with associated exploratory studies supported by the National Institute for Health Research (NIHR). It is a phase 2a, multi-centre, randomised, double bind, placebo controlled, cross-over trial for PBC patients with pruritus. The primary objective is to investigate the safety and tolerability of repeat doses of GSK2330672, and explore whether GSK2330672 administration for 14 days improves pruritus compared with placebo. The key outcomes include improvement in pruritus scores evaluated on a numerical rating scale and other PBC symptoms in an electronic diary completed twice daily by the patients. The secondary outcomes include the evaluation of the effect of GSK2330672 on total serum bile acid (BA) concentrations, serum markers of BA synthesis and steady-state pharmacokinetics of ursodeoxycholic acid (UDCA). DISCUSSION: BAT117213 study is the first randomised controlled crossover trial of ileal bile acid transporter inhibitor, a novel class of drug to treat pruritus in PBC. The main strengths of the trial are utility of a novel, study specific, electronic symptom diary as patient reported outcome to measure the treatment response objectively and the crossover design that allows estimating the treatment effect in a smaller number of patients. The outcome of this trial will inform the trial design of future development phase of the IBAT inhibitor drug. The trial will also provide opportunity to conduct metabonomic and gut microbiome studies as explorative and mechanistic research in patients with cholestatic pruritus. TRIAL REGISTRATION: EudraCT number: 2012-005531-84, ClinicalTrials.gov Identifier: NCT01899703 , registered on 3(rd) July 2013.
Assuntos
Cirrose Hepática Biliar/complicações , Metilaminas/uso terapêutico , Transportadores de Ânions Orgânicos Dependentes de Sódio/antagonistas & inibidores , Prurido/tratamento farmacológico , Simportadores/antagonistas & inibidores , Tiazepinas/uso terapêutico , Adolescente , Adulto , Idoso , Ácidos e Sais Biliares/sangue , Biomarcadores/sangue , Colagogos e Coleréticos/farmacocinética , Colagogos e Coleréticos/uso terapêutico , Estudos Cross-Over , Quimioterapia Combinada , Feminino , Humanos , Masculino , Metilaminas/administração & dosagem , Metilaminas/efeitos adversos , Metilaminas/farmacocinética , Pessoa de Meia-Idade , Transportadores de Ânions Orgânicos Dependentes de Sódio/uso terapêutico , Prurido/etiologia , Simportadores/uso terapêutico , Tiazepinas/administração & dosagem , Tiazepinas/efeitos adversos , Tiazepinas/farmacocinética , Ácido Ursodesoxicólico/farmacocinética , Ácido Ursodesoxicólico/uso terapêutico , Adulto JovemRESUMO
Any statistical model should be identifiable in order for estimates and tests using it to be meaningful. We consider statistical analysis of physiologically-based pharmacokinetic (PBPK) models in which parameters cannot be estimated precisely from available data, and discuss different types of identifiability that occur in PBPK models and give reasons why they occur. We particularly focus on how the mathematical structure of a PBPK model and lack of appropriate data can lead to statistical models in which it is impossible to estimate at least some parameters precisely. Methods are reviewed which can determine whether a purely linear PBPK model is globally identifiable. We propose a theorem which determines when identifiability at a set of finite and specific values of the mathematical PBPK model (global discete identifiability) implies identifiability of the statistical model. However, we are unable to establish conditions that imply global discrete identifiability, and conclude that the only safe approach to analysis of PBPK models involves Bayesian analysis with truncated priors. Finally, computational issues regarding posterior simulations of PBPK models are discussed. The methodology is very general and can be applied to numerous PBPK models which can be expressed as linear time-invariant systems. A real data set of a PBPK model for exposure to dimethyl arsinic acid (DMA(V)) is presented to illustrate the proposed methodology.
Assuntos
Ácido Cacodílico/farmacocinética , Exposição Ambiental , Poluentes Ambientais/farmacocinética , Modelos Biológicos , Modelos Estatísticos , Animais , Teorema de Bayes , Biotransformação , Ácido Cacodílico/efeitos adversos , Ácido Cacodílico/urina , Simulação por Computador , Exposição Ambiental/efeitos adversos , Poluentes Ambientais/efeitos adversos , Poluentes Ambientais/urina , Humanos , Modelos Lineares , Metilaminas/farmacocinética , Camundongos , Medição de RiscoRESUMO
In vitro gut sac experiments were performed on freshwater and 60% seawater acclimated trout (Oncorhynchus mykiss) under treatments designed to discern possible mechanisms of intestinal ammonia transport. Seawater acclimation increased ammonia flux rate into the serosal saline (Jsamm) in the anterior intestine, however it did not alter Jsamm in the mid- or posterior intestine suggesting similar mechanisms of ammonia handling in freshwater and seawater fish. Both fluid transport rate (FTR) and Jsamm were inhibited in response to basolateral ouabain treatment, suggesting a linkage of ammonia uptake to active transport, possibly coupled to fluid transport processes via solvent drag. Furthermore, decreases in FTR and Jsamm caused by low Na(+) treatment indicated a Na(+) linked transport mechanism. Mucosal bumetanide (10(-4) M) had no impact on FTR, yet decreased Jsamm in the anterior and mid-intestine, suggesting NH4(+) substitution for K(+) on an apical NKCC, and at least a partial uncoupling of ammonia transport from fluid transport. Additional treatments (amiloride, 5-(N-ethyl-N-isopropyl)amiloride (EIPA), phenamil, bafilomycin, 4',6-diamidino-2-phenylindole (DAPI), high sodium) intended to disrupt alternative routes of Na(+) uptake yielded no change in FTR or Jsamm, suggesting the absence of direct competition between Na(+) and ammonia for transport. Finally, [(14)C]methylamine permeability (PMA) measurements indicated the likely presence of an intestinal Rh-mediated ammonia transport system, as increasing NH4Cl (0, 1, 5 mmol l(-1)) concentrations reduced PMA, suggesting competition for transport through Rh proteins. Overall, the data presented in this paper provide some of the first insights into mechanisms of teleost intestinal ammonia transport.
Assuntos
Aclimatação/fisiologia , Amônia/metabolismo , Mucosa Intestinal/metabolismo , Oncorhynchus mykiss/fisiologia , Sódio/metabolismo , Amilorida/farmacologia , Animais , Transporte Biológico/efeitos dos fármacos , Transporte Biológico/fisiologia , Bumetanida/farmacologia , Água Doce , Intestinos/efeitos dos fármacos , Metilaminas/metabolismo , Metilaminas/farmacocinética , Oncorhynchus mykiss/metabolismo , Técnicas de Cultura de Órgãos/métodos , Permeabilidade , Água do Mar , Inibidores de Simportadores de Cloreto de Sódio e Potássio/farmacologiaRESUMO
The successful launches of dipeptidyl peptidase IV (DPP IV) inhibitors as oral anti-diabetics warrant and spur the further quest for additional chemical entities in this promising class of therapeutics. Numerous pharmaceutical companies have pursued their proprietary candidates towards the clinic, resulting in a large body of published chemical structures associated with DPP IV. Herein, we report the discovery of a novel chemotype for DPP IV inhibition based on the C-(1-aryl-cyclohexyl)-methylamine scaffold and its optimization to compounds which selectively inhibit DPP IV at low-nM potency and exhibit an excellent oral pharmacokinetic profile in the rat.
Assuntos
Dipeptidil Peptidase 4/metabolismo , Inibidores da Dipeptidil Peptidase IV/síntese química , Inibidores da Dipeptidil Peptidase IV/farmacocinética , Descoberta de Drogas , Metilaminas/síntese química , Metilaminas/farmacocinética , Adamantano/análogos & derivados , Adamantano/química , Adamantano/farmacologia , Administração Oral , Animais , Células CACO-2 , Cristalografia por Raios X , Ciclização , Inibidores da Dipeptidil Peptidase IV/química , Inibidores da Dipeptidil Peptidase IV/farmacologia , Ativação Enzimática/efeitos dos fármacos , Humanos , Concentração Inibidora 50 , Metilaminas/química , Metilaminas/farmacologia , Estrutura Molecular , Nitrilas/química , Nitrilas/farmacologia , Pirazinas/química , Pirazinas/farmacologia , Pirrolidinas/química , Pirrolidinas/farmacologia , Ratos , Fosfato de Sitagliptina , Triazóis/química , Triazóis/farmacologia , VildagliptinaRESUMO
Malaria continues to have a significant impact on the health of the developing world. Efforts to combat this disease now focus on combination therapy in order to stem the emergence of resistant parasites. Continued efforts are needed to discover and develop new agents for use in combination antimalarial regimens. MK-4815 is a small molecule with antimalarial activity that was identified from a large pharmaceutical compound collection using a semiautomated version of a well-established in vitro assay for the erythrocytic stages of Plasmodium falciparum. In vitro studies indicate that the compound selectively accumulates in infected red blood cells and is most effective against the metabolically active late trophozoite/early schizont stages. A variety of drug-resistant field isolates of P. falciparum were found to be as sensitive to MK-4815 as the wild-type lines. MK-4815 is orally active in a P. berghei mouse model of acute malaria. In this model, where untreated animals succumb to infection 10 to 12 days postinfection, MK-4815 was completely curative when given as a single dose of 50 mg/kg, 2 doses of 25 mg/kg, or 4.5 doses of 12.5 mg/kg. In pharmacokinetic studies with mice and rhesus monkeys, MK-4815 demonstrated oral bioavailability and low clearance. In addition, MK-4815 is inexpensive to synthesize, an important characteristic for providing affordable antimalaria therapy to the developing world. The attractive biological and pharmaceutical profile of MK-4815 demonstrates its potential for use in combination with other agents in the fight against malaria.
Assuntos
Antimaláricos/farmacologia , Malária/tratamento farmacológico , Metilaminas/farmacocinética , Fenóis/farmacocinética , Plasmodium falciparum/efeitos dos fármacos , Administração Oral , Animais , Antimaláricos/síntese química , Antimaláricos/farmacocinética , Antimaláricos/uso terapêutico , Disponibilidade Biológica , Esquema de Medicação , Combinação de Medicamentos , Feminino , Humanos , Concentração Inibidora 50 , Macaca mulatta , Malária/mortalidade , Malária/parasitologia , Metilaminas/síntese química , Metilaminas/química , Camundongos , Camundongos Endogâmicos BALB C , Fenóis/síntese química , Fenóis/química , Plasmodium berghei/efeitos dos fármacos , Plasmodium berghei/fisiologia , Plasmodium falciparum/fisiologia , Taxa de Sobrevida , Trofozoítos/efeitos dos fármacos , Trofozoítos/fisiologiaRESUMO
Flavin-containing monooxygenase (FMO) catalyzes the oxygenation of a wide variety of medicines and dietary-derived compounds. However, little information is available regarding drug interactions mediated by FMO3 in vivo. Consequently, we investigated interactions between FMO substrates in humanized-liver mice. Trimethylamine-d9 and itopride were, respectively, intravenously and orally administered to humanized-liver mice (n = 5-7). The pharmacokinetic profiles of itopride (the victim drug) in the presence of trimethylamine (the perpetrator drug) were determined for 24 h after co-administration using liquid chromatography/tandem mass spectrometry. Itopride (10 mg/kg) was extensively oxygenated in humanized-liver mice to its N-oxide. The plasma concentrations of itopride N-oxide after co-administration of itopride and trimethylamine (10 and 100 mg/kg) were significantly suppressed in a dose-dependent manner, but only during the early phase, i.e., up to 2 h after co-administration. With the higher dose of trimethylamine, the areas under the concentration-time curves of itopride and its N-oxide significantly increased (1.6-fold) and decreased (to 60%), respectively; modeling suggested that these modified pharmacokinetics resulted from suppression of the in vivo hepatic intrinsic clearance (to 67%). These results suggest that food-derived trimethylamine may result in interactions with FMO drug substrates immediately after administration; however, the potential for this to occur in vivo may be limited.
Assuntos
Benzamidas/metabolismo , Compostos de Benzil/metabolismo , Fígado/metabolismo , Metilaminas/metabolismo , Oxigenases/metabolismo , Animais , Benzamidas/química , Benzamidas/farmacocinética , Compostos de Benzil/química , Compostos de Benzil/farmacocinética , Interações Medicamentosas , Fígado/química , Masculino , Metilaminas/química , Metilaminas/farmacocinética , Camundongos , Camundongos Transgênicos , Oxigenases/químicaRESUMO
The functions and mechanisms of GPR40 receptor to ameliorating the Alzheimer's disease (AD) by external treatment of encephalopathy remain unknown. In present study, the typical Aß1-42 induced mice model was applied to explore the functions and mechanisms of GPR40 receptor by external treatment of encephalopathy in AD. GPR40 agonist GW9508 and antagonist GW1100 were given by i.g injection to activate/inhibit the GPR40 receptor respectively in the gut of AD mouse which illustrated the function and mechanism of GPR40 receptor in ameliorating AD symptoms by external treatment of encephalopathy. A series of behavioral experiments were used to investigate the cognitive function and memory ability of mice, while molecular biology experiments such as Western blot, ELISA, flow cytometry were used to detect the corresponding changes of signaling pathways. The results revealed that intragastric administrated GW9508 could significantly ameliorate cognitive deficits of AD mouse, up-regulate the expression levels of gut-brain peptides both in blood circulation and hypothalamus thus up-regulate the expression levels of α-MSH in hypothalamus, while the negative autophagy-related proteins and inflammation-related proteins were down-regulated correspondingly. Meanwhile, GW9508 could also inhibit the pathological process of neuroinflammation in microglia. GW1100 reversed the effects of GW9508 significantly. These results suggested that GPR40 was an underlying therapeutic target for the external treatment of encephalopathy related to AD and GPR40 agonist could be explored as the emerging AD therapeutic drug.
Assuntos
Doença de Alzheimer/tratamento farmacológico , Disfunção Cognitiva/tratamento farmacológico , Metilaminas/administração & dosagem , Doenças Neuroinflamatórias/tratamento farmacológico , Propionatos/administração & dosagem , Receptores Acoplados a Proteínas G/agonistas , Administração Oral , Doença de Alzheimer/complicações , Doença de Alzheimer/imunologia , Doença de Alzheimer/patologia , Peptídeos beta-Amiloides/administração & dosagem , Peptídeos beta-Amiloides/toxicidade , Animais , Técnicas de Observação do Comportamento , Barreira Hematoencefálica/metabolismo , Disfunção Cognitiva/diagnóstico , Disfunção Cognitiva/imunologia , Disfunção Cognitiva/patologia , Regulação para Baixo/efeitos dos fármacos , Humanos , Hipotálamo/efeitos dos fármacos , Hipotálamo/imunologia , Hipotálamo/patologia , Masculino , Metilaminas/farmacocinética , Camundongos , Microglia/efeitos dos fármacos , Microglia/imunologia , Microglia/patologia , Doenças Neuroinflamatórias/diagnóstico , Doenças Neuroinflamatórias/imunologia , Doenças Neuroinflamatórias/patologia , Fragmentos de Peptídeos/administração & dosagem , Fragmentos de Peptídeos/toxicidade , Propionatos/farmacocinética , Receptores Acoplados a Proteínas G/metabolismo , Distribuição TecidualRESUMO
BACKGROUND: Dialysis adequacy is currently judged by measures of urea clearance. However, urea is relatively non-toxic and has properties distinct from large classes of other retained solutes. In particular, intracellularly sequestered solutes are likely to behave differently than urea. METHODS: We studied an example of this class, the aliphatic amine monomethylamine (MMA), in stable haemodialysis outpatients (n = 10) using an HPLC-based assay. RESULTS: Mean MMA levels pre-dialysis in end-stage renal disease subjects were 76 +/- 15 microg/L compared to 32 +/- 4 microg/L in normal subjects (n = 10) (P < 0.001). Mean urea reduction was 62% while the reduction ratio for MMA was 43% (P < 0.01). MMA levels rebounded in the 1 hour post-dialytic period to 85% of baseline, whereas urea levels rebounded only to 47% of baseline. MMA had a much larger calculated volume of distribution compared to urea, consistent with intracellular sequestration. Measures of intra-red blood cell (RBC) MMA concentrations confirmed greater levels in RBCs than in plasma with a ratio of 4.9:1. Because of the intracellular sequestration of MMA, we calculated its clearance using that amount removed from whole blood. Clearances for urea averaged 222 +/- 41 ml/min and for MMA 121 +/- 14 ml/min, while plasma clearance for creatinine was 162 +/- 20 ml/min (P < 0.01, for all differences). Using in vitro dialysis, in the absence of RBCs, solute clearance rates were similar: 333 +/- 6, 313 +/- 8 and 326 +/- 4 ml/min for urea, creatinine and MMA, respectively. These findings suggest that the lower MMA clearance relative to creatinine in vivo is a result of MMA movement into RBCs within the dialyser blood path diminishing its removal by dialysis. CONCLUSION: In conclusion, we find that, in conventional haemodialysis, MMA is not cleared as efficiently as urea or creatinine and raise the possibility that RBCs may limit its dialysis not merely by failing to discharge it, but by further sequestering it as blood passes through the dialyser.
Assuntos
Metilaminas/farmacocinética , Diálise Renal , Adulto , Idoso , Dióxido de Carbono/sangue , Creatinina/metabolismo , Eritrócitos/metabolismo , Feminino , Humanos , Concentração de Íons de Hidrogênio , Masculino , Taxa de Depuração Metabólica , Pessoa de Meia-Idade , Oxigênio/sangue , Ureia/metabolismoRESUMO
INTRODUCTION: Behenyltrimethylammonium chloride (BTAC) and stearic acid (SA) could be associated with each other through salt bridges, and the associated BTAC/SA could build bilayer vesicles with the aid of hinokitiol (HKL). METHOD: The vesicles were prepared by a precipitation method and used to enhance the skin permeation of HKL. RESULTS: In case the molar ratio of BTAC/SA/HKL was 1/1/0, no vesicle was observed on transmission electron microscope photos. When the molar ratio of BTAC/SA/HKL was 1/1/0.4, vesicle was observed together with some agglomerates. When the content of HKL increased to the ratios of 1/1/0.8 and 1/1/1.2, vesicles were exclusively observed. In vitro fluxes for 18 hours through hairless mouse skin of HKL dissolved in alcoholic solutions were less than 1 mg/cm2/h. Whereas the fluxes of HKL encapsulated in the vesicles were about three times higher than that of HKL in the alcoholic solutions. CONCLUSION: The vesicles could be used for the hair growth promotion.
Assuntos
Metilaminas/farmacocinética , Monoterpenos/farmacocinética , Absorção Cutânea/fisiologia , Ácidos Esteáricos/farmacocinética , Tropolona/análogos & derivados , Administração Cutânea , Animais , Cloretos/administração & dosagem , Cloretos/farmacocinética , Portadores de Fármacos/administração & dosagem , Portadores de Fármacos/farmacocinética , Feminino , Metilaminas/administração & dosagem , Camundongos , Camundongos Pelados , Monoterpenos/administração & dosagem , Permeabilidade/efeitos dos fármacos , Pele/efeitos dos fármacos , Pele/metabolismo , Absorção Cutânea/efeitos dos fármacos , Ácidos Esteáricos/administração & dosagem , Tropolona/administração & dosagem , Tropolona/farmacocinéticaRESUMO
Polymorphic human and cynomolgus macaque flavin-containing monooxygenases (FMO) 3 are important oxygenation enzymes for nitrogen-containing drugs. Inter-animal variability of FMO3-dependent drug oxygenations in vivo is suspected in cynomolgus macaques because such variability is evident in humans. Therefore, this follow-up study was performed to investigate the pharmacokinetics of orally administered deuterium-labeled trimethylamine in three cynomolgus macaques genotyped for FMO3. Trimethylamine-d9 was rapidly absorbed and attained plasma concentrations greater than the background levels of non-labeled trimethylamine. Trimethylamine-d9 was then converted to trimethylamine-d9N-oxide. The half-lives, maximum plasma concentrations, and areas under the curve for trimethylamine-d9 and its N-oxygenated metabolite and the total clearance for orally administered trimethylamine-d9 were not different among the heterozygote for Q506K FMO3, the heterozygote for V325I FMO3, and the heterozygote for both S99N and F510S FMO3. Trimethylamine N-oxygenation activities mediated by liver microsomes prepared from the same three animals were not substantially different. However, recombinant proteins of the corresponding cynomolgus FMO3 variants showed apparent reduced trimethylamine N-oxygenation activities compared with the wild-type proteins. This study suggests only limited polymorphic effects on the in vivo catalytic function of cynomolgus FMO3. These findings yield important insights in terms of both quantitative and qualitative variations of polymorphic FMO3 in cynomolgus liver.
Assuntos
Fígado/enzimologia , Metilaminas/farmacocinética , Oxigenases/metabolismo , Administração Oral , Animais , Biotransformação , Genótipo , Macaca fascicularis , Masculino , Metilaminas/administração & dosagem , Metilaminas/sangue , Microssomos Hepáticos/enzimologia , Oxirredução , Oxigenases/genética , Variantes Farmacogenômicos , FenótipoRESUMO
N-ethylhexedrone (NEH) and buphedrone (BUPH) are synthetic drugs structurally related to natural cathinone. These synthetic cathinones (SC) are members of the heterogenous family of new psychoactive substances (NPS), which have caused major concern in scientific and forensic communities over the past years, due to their widespread consume. Thus, there is a constant need for monitoring the use of these new substances and gather knowledge on their metabolism and excretion profiles, in order to try to identify markers of NPS consumption. This study aimed at the identification and quantification of NEH, BUPH and selected phase I metabolites using HPLC-MS/MS. NEH, BUPH and some related metabolites were synthesized in-house and quantified in 24 h mice urine, following single dose administration of each drug (64 mg kg-1, i.p.). NEH and BUPH were quantified in mice urine at 58.3 ± 14.4 and 146.2 ± 14.9 µg mL-1, respectively. Similar metabolic pathways were observed for both drugs. Among the metabolites studied, the most excreted ones derived from N-dealkylation of either NEH or BUPH (at around 80 µg mL-1 of urine). Other metabolites resulting from ketone reduction and ketone reduction combined with N-dealkylation or 4-aryl hydroxylation (detected for the first time in non-ring substituted SC) were also identified and quantified. Urine samples were screened using liquid chromatography-high resolution mass spectrometry and various phase II metabolites, including N-acetylated, glucuronides and dicarboxylic acid conjugates were tentatively identified, some of them for the first time. This work is a contribution to the identification of metabolites from SC that can become potential markers to estimate drug consumption.
Assuntos
Butirofenonas , Cromatografia Líquida de Alta Pressão/métodos , Metilaminas , Medicamentos Sintéticos , Espectrometria de Massas em Tandem/métodos , Alcaloides , Animais , Butirofenonas/química , Butirofenonas/farmacocinética , Butirofenonas/urina , Limite de Detecção , Modelos Lineares , Masculino , Metilaminas/química , Metilaminas/farmacocinética , Metilaminas/urina , Camundongos , Reprodutibilidade dos Testes , Medicamentos Sintéticos/análise , Medicamentos Sintéticos/química , Medicamentos Sintéticos/farmacocinéticaRESUMO
There is a growing body of clinical evidence that supports a strong association between elevated circulating trimethylamine N-oxide (TMAO) levels with increased risk of developing adverse cardiovascular outcomes such as atherosclerosis and thrombosis. TMAO is synthesized through a meta-organismal stepwise process that involves (i) the microbial production of TMA in the gut from dietary precursors and (ii) its subsequent oxidation to TMAO by flavin-containing monooxygenases in the liver. Choline, l-carnitine, betaine, and other TMA-containing compounds are the major dietary precursors of TMA. TMAO can also be absorbed directly from the gastrointestinal tract after the intake of TMAO-rich foods such as fish and shellfish. Thus, diet is an important factor as it provides the nutritional precursors to eventually produce TMAO. A number of studies have attempted to associate circulating TMAO levels with the consumption of diets rich in these foods. On the other hand, there is growing interest for the development of novel food ingredients that reduce either the TMAO-induced damage or the endogenous TMAO levels through the interference with microbiota and host metabolic processes involved in TMAO pathway. Such novel functional food ingredients would offer great opportunities to control circulating TMAO levels or its effects, and potentially contribute to decrease cardiovascular risk. In this review we summarize and discuss current data regarding the effects of TMA precursors-enriched foods or diets on circulating TMAO levels, and recent findings regarding the circulating TMAO-lowering effects of specific foods, food constituents and phytochemicals found in herbs, individually or in extracts, and their potential beneficial effect for cardiovascular health.
Assuntos
Ingredientes de Alimentos/análise , Alimento Funcional/análise , Microbioma Gastrointestinal/fisiologia , Metilaminas/sangue , Metilaminas/farmacocinética , Betaína/metabolismo , Disponibilidade Biológica , Carnitina/metabolismo , Colina/metabolismo , Dieta/métodos , Absorção Gastrointestinal , Trato Gastrointestinal/metabolismo , Fatores de Risco de Doenças Cardíacas , Humanos , Fígado/metabolismo , Oxigenases/metabolismoRESUMO
2-Phenylcyclopropylmethylamine (PCPMA) analogues have been reported as selective serotonin 2C agonists. On the basis of the same scaffold, we designed and synthesized a series of bitopic derivatives as dopamine D3R ligands. A number of these new compounds show a high binding affinity for D3R with excellent selectivity. Compound (1R,2R)-22e and its enantiomer (1S,2S)-22e show a comparable binding affinity for the D3R, but the former is a potent D3R agonist, while the latter acts as an antagonist. Molecular docking studies revealed different binding poses of the PCPMA moiety within the orthosteric binding pocket of the D3R, which might explain the different functional profiles of the enantiomers. Compound (1R,2R)-30q shows a high binding affinity for the D3R (Ki = 2.2 nM) along with good selectivity, as well as good bioavailability and brain penetration properties in mice. These results reveal that the PCPMA scaffold may serve as a privileged scaffold for the design of aminergic GPCR ligands.
Assuntos
Ciclopropanos/farmacocinética , Agonistas de Dopamina/farmacocinética , Antagonistas de Dopamina/farmacocinética , Metilaminas/farmacocinética , Receptores de Dopamina D3/metabolismo , Animais , Sítios de Ligação , Encéfalo/metabolismo , Ciclopropanos/síntese química , Ciclopropanos/metabolismo , Agonistas de Dopamina/síntese química , Agonistas de Dopamina/metabolismo , Antagonistas de Dopamina/síntese química , Antagonistas de Dopamina/metabolismo , Desenho de Fármacos , Ligantes , Metilaminas/síntese química , Metilaminas/metabolismo , Camundongos Endogâmicos ICR , Simulação de Acoplamento Molecular , Estrutura Molecular , Receptor 5-HT2C de Serotonina/metabolismo , Estereoisomerismo , Relação Estrutura-AtividadeRESUMO
Structure-based drug design led to the identification of a novel class of potent, low MW alkylamine renin inhibitors. Oral administration of lead compound 21l, with MW of 508 and IC(50) of 0.47nM, caused a sustained reduction in mean arterial blood pressure in a double transgenic rat model of hypertension.
Assuntos
Anti-Hipertensivos/química , Metilaminas/química , Renina/antagonistas & inibidores , Administração Oral , Sequência de Aminoácidos , Animais , Anti-Hipertensivos/síntese química , Anti-Hipertensivos/farmacocinética , Pressão Sanguínea , Simulação por Computador , Cristalografia por Raios X , Desenho de Fármacos , Humanos , Metilaminas/síntese química , Metilaminas/farmacocinética , Ratos , Ratos Transgênicos , Renina/metabolismo , Relação Estrutura-AtividadeRESUMO
In this study, a simple, fast and sensitive LC/MS/MS method was developed and validated for the determination of GW9508 in rat plasma. The sample was precipitated with acetonitrile and subsequently separated on ZORBAX Eclipse XDB C18 column (50 mm × 2.1 mm, 5 µm). Mobile phase was composed of 0.1% formic acid in water and acetonitrile with gradient elution, at a flow rate of 0.4 mL/min. The analyte and internal standard were quantitatively monitored with precursor-to-product transitions of m/z 348.2â183.1 and m/z 397.2â260.2, respectively. The linearity of the assay was evident in the range of 1-1000 ng/mL with correlation coefficient more than 0.998. The validation parameters were all within the acceptable limits. The validated method has been successfully applied to the pharmacokinetics study of GW9508 in rat plasma, and our results demonstrated that GW9508 showed low clearance, moderate half-life and ideal bioavailability (54.88%). Furthermore, metabolites stemmed from rat plasma, rat hepatocytes and human hepatocytes were analyzed by an LC-Q-Exactive-Orbitrap-MS assay, resulting in the identification of seven metabolites based on the accurate mass and fragment ions. Acylglucuronide conjugate (M6) was found as the most abundant metabolite in all tested matrices. The metabolic pathways were proposed as hydroxylation and glucuronidation. This study provided an overview of disposition of GW9508, which is highly instructive for better understanding the effectiveness and toxicity of this drug.